Lanthanum carbonate was initially approved by the United States Food and Drug Administration (FDA) on October 26, 2004.

Lanthanum carbonate is primarily used to manage hyperphosphatemia, a condition characterized by elevated levels of phosphate in the blood, commonly seen in individuals with chronic kidney disease (CKD) or end-stage renal disease (ESRD). Binding to dietary phosphate in the gastrointestinal tract and inhibiting its absorption helps control and reduce phosphate levels in the body, thereby preventing complications such as bone disorders and cardiovascular issues resulting from high phosphate levels in these patient populations.

Lanthanum carbonate is primarily administered orally. It is available in various forms, including liquid solutions, syrups, and powders, that are meant to be taken by mouth.  Always follow your healthcare provider's instructions regarding the appropriate route and dosage for its administration.

Lanthanum carbonate, like many medications, can cause a range of side effects, both common and less common. Common side effects may include nausea, vomiting, diarrhea, abdominal pain, constipation, and stomach upset. On the other hand, although less frequent, serious side effects can occur, including allergic reactions, intestinal blockage, low levels of vitamins and minerals, excessively low phosphate levels (hypophosphatemia), and gastrointestinal ulcers.

Lanthanum carbonate may cause allergic reactions in some individuals. Prolonged use of this medication can affect the absorption of calcium and vitamin D. This medication is intended to lower phosphate levels in the blood. Its abrupt cessation may lead to an increase in phosphate levels.

If you experience hives, itching, rash, swelling of the face, lips, tongue, or throat, or have difficulty breathing after Lanthanum carbonate, seek immediate medical attention. Regular monitoring of calcium and vitamin D levels is necessary, and supplementation may be required based on your healthcare provider's recommendations.

Lanthanum carbonate should only be used under the supervision of a healthcare provider who can monitor your condition and adjust your treatment plan as necessary. Inform your healthcare provider if you have any kidney-related conditions or if your kidney function changes during treatment. Adjustments to the dosage may be necessary. If you have a history of gastrointestinal disorders, such as inflammatory bowel disease or bowel obstructions, discuss these conditions with your healthcare provider. If you are scheduled for dental surgery, inform your surgeon and healthcare provider that you are taking this medication. If you are following a phosphate-restricted diet, work closely with a dietitian or nutritionist to ensure your dietary choices align with your treatment goals. Avoid phosphate-rich foods and beverages. Regular monitoring of calcium and vitamin D levels may be necessary, as prolonged use of this medication can affect their absorption.

1. Mylan, Electronic Medicines Compendium (EMC), [Revised on 16th Aug 2023] [Accessed on 2nd September 2023], https://www.medicines.org.uk/emc/product/12802/smpc#gref
2. J. Goddard, A.N. Turner, Kidney and urinary tract disease, Davidson's Principles & Practice of Medicine, 22nd Edition, 2014, 461-523.
3. Daniel D. Bikle, Agents That Affect Bone Mineral Homeostasis, Lange's Basic & Clinical Pharmacology, 14th Edition, 2018, 772-791
4. Mylan, US Food and Drug Administration, [Revised on August 2022] [ Accessed on 2nd September 2023],https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021468s023,204734s005lbl.pdf

The drug information on this page is not a substitute for medical advice; it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.